Mycobacterium w immunotherapy
Phase 3Biologic
Mycobacterium w immunotherapy is one of 15 biologic programs targeting Pericarditis. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Pericarditis
#DrugCompanyPhaseTrials
1Colcrys
Alnylam PharmaceuticalsApproved
Bayer Aspirin
BayerApproved
Epidiolex
Jazz PharmaceuticalsApproved
Plaquenil
Alnylam PharmaceuticalsPhase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Rayos
RRoxane Laboratories
Phase 3
RPH-104
UUnknown Sponsor
Phase 3
Kineret
SSwedish Orphan Biovitrum
Phase 2
Mycobacterium w immunotherapy
UUniversity of Cape Town
Phase 3
Spikevax
ModernaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Cape Town